维普中文期刊产品整合服务
1292篇 您的检索式:作者名="Boyd M"
    题名 作者 年代 出处 被引量
1Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis显示文摘Remo Panaccione Subrata Ghosh Stephen Middleton Juan R. Márquez Boyd B. Scott Laurence Flint Hubert JF. van Hoogstraten Annie C. Chen Hanzhe Zheng Silvio Danese Paul Rutgeerts 2013Gastroenterology2013,,:5
2Functional gastrointestinal disorders in eating disorder patients:Altered distribution and predictors using ROME Ⅲ compared to ROME Ⅱ criteria显示文摘AIM:To compare the prevalence of Functional gastrointestinal disorders(FGIDs)using ROMEⅢand ROMEⅡand to describe predictors of FGIDs among eating disorder(ED)patients.METHODS:Two similar cohorts of female ED inpatients,aged 17-50 years,with no organic gastrointestinal or systemic disorders,completed either the ROMEⅢ(n=100)or the ROMEⅡ(n=160)questionnaire on admission for ED treatment.The two ROME cohorts were compared on continuous demographic variables(e.g.,age,BMI)using Student’s t-tests,and on categorical variables(e.g.,ED diagnosis)usingχ2-tests.The relationship between ED diagnostic subtypes and FGID categories was explored usingχ2-tests.Age,BMI,and psychological and behavioural predictors of the common(prevalence greater than 20%)ROMEⅢFGIDs were tested using logistic regression analyses.RESULTS:The criteria for at least one FGID were fulfilled by 83%of the ROMEⅢcohort,and 94%of the ROMEⅡcohort.There were no significant differences in age,BMI,lowest ever BMI,ED diagnostic subtypes or ED-related quality of life(QOL)scores between ROMEⅡand ROMEⅢcohorts.The most prevalent FGIDs using ROMEⅢwere postprandial distress syndrome(PDS)(45%)and irritable bowel syndrome(IBS)(41%),followed by unspecified functional bowel disorders(U-FBD)(24%),and functional heartburn(FH)(22%).There was a 29%or 46%increase(depending on presence or absence of cyclic vomiting)in functional gastroduodenal disorders because of the introduction of PDS in ROMEⅢcompared to ROMEⅡ.There was a 35%decrease in functional bowel disorders(FBD)in RomeⅢ(excluding U-FBD)compared to ROMEⅡ.The most significant predictor of PDS was starvation(P=0.008).The predictor of FH(P=0.021)and U-FBD(P=0.007)was somatisation,and of IBS laxative use(P=0.025).Age and BMI were not significant predictors.The addition of the 6-mo duration of symptoms requirement for a diagnosis in ROMEⅢadded precision to many FGIDs.CONCLUSION:ROMEⅢconfers higher precision in diagnosing FGIDs but self-induced vomiting should be excluded from the diagnosis of cyclic vomiting.Psychological factors appear to be more influential in ROMEⅡthan ROMEⅢ.Xiaojie Wang Georgina M Luscombe Catherine Boyd John Kellow Suzanne Abraham 2014World Journal of Gastroenterology2014,20,43:4
3Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders显示文摘E Joanna Baxter Linda M Scott Peter J Campbell Clare East Nasios Fourouclas Soheila Swanton George S Vassiliou Anthony J Bench Elaine M Boyd Natasha Curtin Mike A Scott Wendy N Erber Anthony R Green 2005The Lancet . 2005 (9464)2005,,:2
4Is it the time to reconsider the choice of valves for cardiac surgery: mechanical or bioprosthetic?显示文摘Valvular heart disease is a pathologic processinvolving one or more of the four valves (aortic,pulmonary, mitral and tricuspid) of the heart typified bystenosis or regurgitation and leading to patient symp-toms. The most common causes are tissue degeneration,rheumatic fever and congenital heart diseases. Aorticvalve replacement (AVR) using either mechanical orbioprosthetic (tissue) valves via open-heart surgicalAVR (SAVR) is the most widely accepted standardtreatment.Patricia M Applegate W. Douglas Boyd Richard L. Applegate, Ⅱ Hong Liu 2017The Journal of Biomedical Research2017,31,5:2
5Long-term follow-up of aviators after functional endoscopic sinus surgery for sinus barotrauma显示文摘PARSONS D S CHAMBERS D W BOYD E M 1997Aviat Space Environ Med1997,68,:1
6Toxicity of mono-,di- and tri-chlorophenols to lux marked terres- trial bacteria,Burkholderia species Rasc c2 and Pseudomonas fluorescens 显示文摘Boyd E M Killham K Meharg A A 2002Chemosphere2002,43,2:1
7Ovarian carcinoma subtypes are different disease:implications for biomarker studies显示文摘Kobel M Kalloger S E Boyd N 2008PLos Med2008,5,12:1
8Wernicke encephalopathy complicating lymphoma therapy:case report and literature review显示文摘Boniol S Boyd M Koreth R et al 2007South Med J2007,100,7:1
9Superluminal and Slow Light Propagation in a Room- Temperature Solid显示文摘BIGELOW M S LEPESHKIN N N BOYD R W 2003Science2003,301,:1
10Safety, effectiveness and ease of use of a nonreusable syringe in a developing country immmunization program显示文摘Steinglass RS Boyd D Grabowsky M 1995Bull WHO1995,73,:1
11Involvement of heparanase in tumor metastases : a new target in cancer therapy显示文摘Boyd DD Nakajima M 2004J Natl Cancer Ins2004,96,16:1
12Security- Mediated certificateless cryptography 显示文摘CHOW S S M BOYD C NIETO J M G 2006Lecture Notes in Computer Science2006,3958,:1
13Dynamic fault tree models for fault tolerant computer systems 显示文摘DUGAN J B BAVUSO S J BOYD M A 1992IEEE Transactions on Reliability1992,41,3:1
14Lysyl oxi- dase in development, aging and pathologies of the skin 显示文摘SZAUTER K M CAO T BOYD C D 2005Pathologie Biologie2005,53,7:1
15The effects of environmental liability on industrial real estate development 显示文摘Boyd J Harrington W Macauley M K 1996Journal of Real Estate Finance and Economics1996,12,1:1
16Dynamic Fault-Tree Models for Fault-Tolerant Computer Systems 显示文摘Bechta Dugan J Bavuso S J Boyd M A 1992IEEE Trans on Reliability1992,41,3:1
17Teams,tribes and patient safety:overcoming barriers to effective teamwork in healthcare显示文摘Weller J Boyd M Cumin D 2014Postgrad Med J2014,90,1061:1
18Regulation of p53and MDM2activity by MTBP显示文摘Brady M Vlatkovic N Boyd MT 2005Mol Cell Biol2005,25,2:1
19Attenuating organic contaminant mobility by soil modification显示文摘Boyd S A Lee J F Mortland M M 1988Nature1988,333,26:1
20Lyotropic liquid crystalline phases formed from glycerate surfactants as sustained release drug delivery systems显示文摘Boyd B J Whittaker D V Khoo S M 2006Int J Pharm2006,309,:1
返回顶部 每页显示:
共65页 首页 上一页 第1页 下一页 末页 /65 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费